Loading...

TRDA ENTRADA THERAPEUTICS INC Expansion Plans 8-K Filing

NTRD

TRD

ENTRADA THERAPEUTICS INC

(TRDA)

2025 8-K

Show Summary

Show Summary

Financial Statements

Workforce Reductions

Clinical Trial Authorization

Financial Results

Clinical Trial Authorization

Financial Update

Financial Results

Financial Results

Securities Purchase Agreement

Update on ENTR-601-44

Annual Meeting and Amendmen...

Financial Results Announcement

Financial Results Announcement

Management Change

Resignations and Appointments

Update on ENTR-601-44

Financial Results Announcement

Amendment to License Agreem...

Sales Agreement

Clinical Trial Announcement

Appointment of Director

Financial Results Announcement

Clinical Trial Authorization

Resignation and Annual Meeting

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Strategic Collaboration and...

External Links:

On March 24, 2025, Entrada Therapeutics announced it received authorization from UK regulators to start a clinical trial for ENTR-601-45, aimed at treating Duchenne muscular dystrophy. The trial will evaluate the safety and effectiveness of the drug

AI Assistant

ENTRADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.